Singapore, 14 March 2025 – Actxa Pte Ltd, a pioneer in AI-driven preventive healthcare, has been recognised as the Best AI-Driven Preventive HealthTech Company 2025 at the Singapore Business Awards hosted by APAC Insider. This award celebrates Actxa's dedication to improving health through technology, especially in the growing field of preventive healthcare. This recognition highlights Actxa's mission to create next-generation preventive healthcare solutions using artificial intelligence (“AI”) and data analytics. BGEM, the world’s first non-invasive glucose monitoring solution, is a standout innovation by Actxa that provides valuable insights into glucose health and diabetic risk. By enabling users to monitor their glucose trends non-invasively, BGEM helps them make informed lifestyle choices and reduce their risk of chronic conditions like diabetes. “Receiving the Best AI-Driven Preventive HealthTech Company award is an immense honour for us,” said Marcus Soo, CEO of Actxa. “I would like to dedicate this award to our team for their hard work, commitment, and visionary approach. Preventive health is at the heart of everything we do, giving people personalised, real-time insights using AI so they can make healthier decisions.” Actxa’s impact doesn’t stop with individual health. The company is also aligned with Singapore’s Healthier SG initiative, which aims to shift the focus of healthcare toward prevention. With tools like VO2 Max measurement and Sleep Track™, Actxa empowers people with the knowledge to lead healthier, more active lives. At Actxa, the focus is on more than just technology—it is about using innovation to improve the well-being of individuals and communities. Their core values—innovation, excellence, integrity, empathy, and inclusiveness—are reflected in every product, from BGEM technologies to the Sense 2 Smart Scale and Spark+ Series 2 fitness trackers. At its core, Actxa is driven by a vision to help people live healthier and longer with technology. For further information, please contact:   ​Tan Lay Eng   Communications Manager  layeng.tan@actxa.com   +65 9877 0406  Hasyimah Begum AJ  Communications Executive  hasyimah.aj@actxa.com   +65 8780 3620   About Actxa   Headquartered in Singapore, Actxa Pte Ltd is a deep tech company founded in 2015 that leverages artificial intelligence to create next generation preventive healthcare solutions. ​  We create evidence-based, personalised health insights in the domains of physical activities, sleep quality, body composition, stress and recovery, heart health and blood glucose evaluation and monitoring. ​​   To improve population health, Actxa establishes worldwide partnerships and research collaborations to develop critical preventive health models to help people avert chronic diseases such as diabetes and hypertension.​​     ​Learn more about Actxa at www.actxa.com .

Singapore, 9 November 2024 – Actxa, a Singapore-based deep tech company, showcased its cutting-edge solutions at World Diabetes Day 2024, organised by Diabetes Singapore at Toa Payoh HDB Hub Mall on 9 and 10 November. Over the weekend, Actxa featured its Blood Glucose Evaluation & Monitoring (“BGEM”) technology – the world’s first non-invasive blood glucose monitoring solution powered by a cloud-based AI-driven algorithm. The event was graced by Ms Rahayu Mahzam, Minister of State, Ministry of Digital Development and Information & Ministry of Health, as the Guest of Honour, emphasising the critical importance of combating diabetes in Singapore. Non-Invasive Diabetes Monitoring with BGEM Technology At the heart of Actxa’s booth was the BGEM technology, which marks a new approach to early diabetes detection and management. BGEM leverages wearables with photoplethysmography (“PPG”) sensors to collect essential data, in which an AI model computes the relevant digital biomarkers correlated with prediabetes or Type 2 Diabetes Mellitus (T2DM) to assess diabetic risk and generate predicted blood glucose results to support early intervention. BGEM predicts and classifies blood glucose levels as either “Normal” or “Elevated” and assesses the risk of Type 2 diabetes based on the last three days of measurement results. Personalised health tips were also shared with users to encourage ongoing wellness. During the two-day event, attendees had the opportunity to experience live demonstrations of the BGEM solution, which offers blood glucose predictions and classifications within five minutes using smart rings. Transforming Health with Preventive Technology Marcus Soo, Chief Executive Officer of Actxa, said, "Actxa is excited to be a gold sponsor at World Diabetes Day 2024 as we continue our journey to translate technological innovations into evident solutions that enhance lives. Diabetes remains one of Singapore's most urgent public health challenges, and we are committed to making impactful, accessible solutions for early detection and chronic disease management. BGEM exemplifies our dedication to providing tools that empower people to make proactive health choices. We envision a future where managing chronic conditions like diabetes is made more attainable for all, building healthier communities together.” Other Key Highlights from Actxa’s Booth · Health Insights with the Sense 2 Smart Scale: Attendees received free body composition analysis reports, including body fat percentage, muscle mass, and metabolic rate, that empower them to restructure their lifestyle habits and achieve their desired health goals. · Exclusive Product Discounts: Special event discounts on Actxa’s products, including the Spark+ Series 2 activity trackers and Sense 2 Smart Scale, were offered to support individuals’ journey toward better health. Download event photos here . For further information, please contact:   ​Tan Lay Eng   Communications Manager  layeng.tan@actxa.com   +65 9877 0406  Hasyimah Begum AJ  Communications Executive  hasyimah.aj@actxa.com   +65 8780 3620   About Actxa   Headquartered in Singapore, Actxa Pte Ltd is a deep tech company founded in 2015 that leverages artificial intelligence to create next generation preventive healthcare solutions. ​  We create evidence-based, personalised health insights in the domains of physical activities, sleep quality, body composition, stress and recovery, heart health and blood glucose evaluation and monitoring. ​​   To improve population health, Actxa establishes worldwide partnerships and research collaborations to develop critical preventive health models to help people avert chronic diseases such as diabetes and hypertension.​​     ​Learn more about Actxa at www.actxa.com .

Singapore, 17 October 2024  —Actxa Pte Ltd, a Singapore-based deep tech company, introduces its Blood Glucose Evaluation & Monitoring (BGEM) technology . Powered by a cloud-based AI-driven algorithm, BGEM offers a non-invasive solution for blood glucose monitoring, marking a new approach to early diabetes detection and management. Diabetes: A Growing Concern In Singapore, it is projected that by 2050, at least 1 million people will be living with diabetes, with 1 out of 4 remaining undiagnosed¹. Globally, the number of diabetic individuals is expected to reach about 643 million by 2030, with 1 in 2 adults undiagnosed². Undiagnosed diabetes poses severe risks, as early-stage symptoms are often silent, leading to delayed diagnosis and potentially irreversible complications. Regular glucose monitoring is essential for detecting the risk of diabetes early, which enables timely and life-saving interventions. A Non-Invasive Approach to Blood Glucose Monitoring BGEM leverages advanced photoplethysmography (PPG) sensors to offer a non-invasive blood glucose monitoring solution. By integrating this technology into wearables, BGEM allows users to monitor their diabetic risk assessment regularly. This could support and promote early intervention, leading to better health outcomes while reducing long-term pain and cost for individuals.  A joint study by Actxa and KK Women’s and Children’s Hospital (“KKH”), titled   “Utility of photoplethysmography in detecting elevated blood glucose among non-diabetics” and published in the Singapore Medical Journal, validates the effectiveness of PPG sensors in its non-invasive blood glucose detection. The study highlights BGEM’s capabilities in integrating wearable devices with PPG sensors to assess the risk of impaired glucose regulation. The full study can be accessed here .   BGEM leverages wearables with PPG sensors to collect essential data, in which an AI model computes the relevant digital biomarkers correlated with prediabetes or Type 2 Diabetes Mellitus (T2DM) to assess diabetic risk and generate predicted blood glucose results to support early intervention. [Image Source: Actxa] Clinical Validation and Global Partnerships BGEM underwent its first clinical trials in 2022, with its first scientific paper published in 2023. The technology has garnered attention for its potential in non-invasive blood glucose monitoring. Actxa continues to collaborate with international partners to explore the broader potential of BGEM, bringing it to markets globally while remaining committed to advancing local innovations in Singapore. Alleviating Financial Strain Through Diabetes Prevention With diabetes on the rise globally, the focus is shifting from reactive treatment to proactive prevention. BGEM’s early detection capabilities enable individuals to make lifestyle changes that can prevent or delay the onset of Type 2 diabetes mellitus (T2DM). By reducing the burden of long-term diabetes management, BGEM contributes to healthier populations and more sustainable healthcare systems. In Singapore, the healthcare system faces significant strain due to the rising number of diabetes cases, with around $940 million spent on diabetes-related care in 2017³. By enabling earlier detection and intervention, BGEM has the potential to ease this burden, contributing to more sustainable healthcare outcomes. Innovating for a Healthier Future Marcus Soo, Chief Executive Officer of Actxa, said , “As a company with a vision to help people live healthier and longer lives through technology, we are dedicated to translating technological innovations into evident solutions that enhance lives. BGEM simplifies the monitoring process, allowing users to gain insights into their health regularly and non-invasively. By continuing to collaborate with partners and refine our technology, we hope to empower more individuals to manage their health proactively. We believe this can lead to better outcomes and support the sustainability of healthcare systems.” Actxa is committed to improving the lives of those affected by diabetes through cutting-edge technology and meaningful collaborations. References: https://www.healthhub.sg/live-healthy/1273/d-day-for-diabetes https://idf.org/aboutdiabetes/what-is-diabetes/factsfigures.html#:~:text=The%20total%20number%20of%20people,living%20with%20dia   betes%20are%20undiagnosed   https://www.moh.gov.sg/news-highlights/details/percentage-of-spending-on-mental-health-diabetes-and-ageing-versus-total-healthcare-spending-in-2018-against-amount-budgeted-for-2019/   For further information, please contact:   ​Tan Lay Eng   Communications Manager  layeng.tan@actxa.com   +65 9877 0406  Hasyimah Begum AJ  Communications Executive  hasyimah.aj@actxa.com   +65 8780 3620   About Actxa   Headquartered in Singapore, Actxa Pte Ltd is a deep tech company founded in 2015 that leverages artificial intelligence to create next generation preventive healthcare solutions. ​  We create evidence-based, personalised health insights in the domains of physical activities, sleep quality, body composition, stress and recovery, heart health and blood glucose evaluation and monitoring. ​​   To improve population health, Actxa establishes worldwide partnerships and research collaborations to develop critical preventive health models to help people avert chronic diseases such as diabetes and hypertension.​​     ​Learn more about Actxa at www.actxa.com .

A local study shows that sensors commonly found in wearables can aid in the non-invasive detection of elevated blood glucose levels (Image source: Stock image) Singapore, 10 October 2024  – Imagine detecting the risk of diabetes with a wearable device, allowing for early intervention through positive lifestyle changes to delay or even prevent the development of this chronic disease.   Type 2 diabetes mellitus (T2DM) is a global non-communicable disease, with cases surging from 108 million in 1980 to 422 million in 2014[1]. Recognising the importance of early detection and intervention, Actxa Pte Ltd (Actxa) partnered with KK Women’s and Children’s Hospital (KKH) on a research study.   This study, “ Utility of photoplethysmography in detecting elevated blood glucose among non-diabetics” , recently published in the Singapore Medical Journal, shows that using photoplethysmography (PPG) signals (the green or red light on most wearables that measure heart rate), a non-invasive method of assessing T2DM risk, is a viable option to provide a more cost-effective and more accessible modality for screening in the community. The full study can be accessed here .      From October 2021 to February 2023, healthy volunteers were recruited at KKH. 483 volunteers’ capillary glucose levels were measured alongside PPG signals using Actxa’s Spark + Series 2 activity tracker and an in-ear wearable. The volunteers were evaluated over eight minutes to obtain accurate PPG readings.     Participants with capillary glucose levels of 11.1 mmol/dL or less consumed a standard glucose tolerance drink (TRUTOL. 75 g) and returned one hour later for a follow-up test. In contrast, those with readings exceeding 11.1 mmol/dL were exempted from the glucose tolerance drink. This methodology ensured the thorough evaluation of blood glucose levels, thereby enhancing the reliability of the study’s findings.    This research leverages the innovative use of PPG sensors to monitor and evaluate increased blood glucose levels non-invasively. The study has revealed that non-invasive diabetes risk assessment using PPG is a practical and cost-effective method for population-wide screening. This non-invasive nature of the PPG approach makes it accessible, encouraging early detection and allowing individuals to adopt timely positive lifestyle changes and seek medical interventions before more severe complications develop.    This study has also demonstrated the capabilities of Actxa’s Blood Glucose Evaluation & Monitoring (BGEM) technology, the world’s first non-invasive diabetes risk assessment powered by an AI-driven algorithm. BGEM is a cloud-based technology that can be seamlessly integrated into wearable devices with PPG sensors to assess the risk of impaired glucose regulation.     As countries grapple with rising healthcare costs related to diabetes care, this technology can potentially reduce long-term healthcare burden by focusing on prevention. Early detection enables individuals to make lifestyle changes that can prevent or delay the onset of T2DM, ultimately leading to healthier populations and more sustainable healthcare systems.    Marcus Soo, Chief Executive Officer of Actxa, said , “In our pursuit of innovative solutions to address global health challenges, Actxa is proud that our technology has been validated through a local study. We are on track to reveal a transformative breakthrough in how we evaluate prediabetes and T2DM risk using PPG sensors.     Actxa’s BGEM technology, which integrates into wearables with PPG sensors, offers a cost-effective and scalable method for non-invasive blood glucose risk assessment, positioning us at the forefront of preventive health technology.     The opportunities here are paradigm-shifting—a wearable device on your wrist, finger, or ear could detect early diabetes risks, enabling individuals to make proactive lifestyle changes. This collaboration reflects our commitment to pushing preventive healthcare innovation, making early detection and prevention accessible for all. Together with our partners, we are charting the course towards a healthier future for individuals and our communities.”    Future developments will involve incorporating various non-invasive detection sensors to enhance sensitivity and specificity, enabling better management of T2DM through non-invasive methods alongside capillary glucose measurements.   Reference:   1. WHO Factsheet on Diabetes: https://www.who.int/news-room/fact-sheets/detail/diabetes     For further information, please contact:   ​Tan Lay Eng   Communications Manager  layeng.tan@actxa.com   +65 9877 0406  Hasyimah Begum AJ  Communications Executive  hasyimah.aj@actxa.com   +65 8780 3620   About Actxa   Headquartered in Singapore, Actxa Pte Ltd is a deep tech company founded in 2015 that leverages artificial intelligence to create next generation preventive healthcare solutions. ​  We create evidence-based, personalised health insights in the domains of physical activities, sleep quality, body composition, stress and recovery, heart health and blood glucose evaluation and monitoring. ​​   To improve population health, Actxa establishes worldwide partnerships and research collaborations to develop critical preventive health models to help people avert chronic diseases such as diabetes and hypertension.​​     ​Learn more about Actxa at www.actxa.com .

25 July 2024  – Actxa Pte Ltd (“Actxa”), a Singaporean AI-driven deep tech company, has entered a Memorandum of Understanding (“MOU”) and a Research and Collaboration Agreement (“RCA”) with Universitas Kristen Krida Wacana (“UKRIDA”), a prominent private institution of higher education that has been committed to education, research, and community service for 56 years in Indonesia, with its Faculty of Medicine and Health Sciences being the oldest at the university.     The MOU and RCA, signed on 24 July 2024, mark a significant milestone for Actxa as it embarks on a collaborative partnership focusing on joint research, product development, higher education, human resources development, and community services in artificial intelligence (“AI”) based chronic disease management. UKRIDA, whose mission is to be at the forefront of healthcare science development, has embraced Artificial intelligence as an avant-garde, innovative technology as a major focus for UKRIDA’s Research and Development efforts. This joint project, therefore, will bring great benefit to both Actxa and UKRIDA, whose interests are perfectly matched.     Since 2017, Actxa has been at the forefront of collaborations with research and medical institutions in Singapore and globally, focusing on developing life-changing preventive health technologies and solutions using AI.  One of Actxa’s most significant achievements is BGEM , the world’s first non-invasive blood glucose monitoring solution. Powered by a cloud-based AI-driven algorithm, BGEM integrates seamlessly with smart wearables and hearables using Photoplethysmography (PPG) sensors to assess the risk of impaired glucose regulation.    UKRIDA’s interest in developing healthcare based on innovative technology has found BGEM to have great potential in glucose metabolism evaluation and control, especially since diabetes mellitus is one of the major metabolic diseases that needs to be prevented and controlled. The joint project with Actxa to further develop BGEM capabilities and adapt them to the Indonesian population will enable UKRIDA to be a pioneer in chronic disease prevention and control technology in Indonesia.  ​   This strategic partnership enables Actxa and UKRIDA, with its motto “Lead to Impact”, to jointly pioneer research and development initiatives leveraging cutting-edge technologies such as AI, Machine Learning (“ML”), and Big Data Analytics. Their collaborative efforts aim to detect, delay, or prevent the onset of chronic diseases. This alliance fosters innovation through the co-creation of healthcare solutions and advanced technologies, coupled with rapid prototyping, to accelerate the market introduction of these products and technologies.    Marcus Soo , Chief Executive Officer of Actxa , said, “We are honoured to partner with UKRIDA, marking a significant milestone for Actxa as we embark on our very first collaboration with an Indonesian university conducting research within a hospital setting. This partnership reflects our shared commitment to innovation and empowering individuals with tools to make informed and positive lifestyle decisions.  We extend our gratitude to our joint venture partner, LIF, for their pivotal role in this close partnership, facilitating our efforts in Indonesia. Together, we aim to drive global innovation in preventive healthcare, leveraging our combined expertise to make meaningful strides in chronic disease prevention and management.”  Prof. Dr.-Ing. Ir. Herman Parung, M.Eng, Rector of UKRDIA, shared, “Both Actxa and UKRIDA share a profound commitment to innovation and the advancement of preventive healthcare solutions. This partnership is poised to accelerate the development of advanced healthcare solutions, ultimately contributing to better health and well-being for individuals and communities.” He also added, “We are confident that this partnership will yield significant advancements in healthcare and foster a strong bond between our institutions.”  This partnership between Actxa and UKRIDA heralds groundbreaking innovations in chronic disease prevention and management, working towards building a healthier future for individuals in Singapore, Indonesia, and worldwide. This joint project will also be an example of UKRIDA’s commitment to developing health science based on innovative technology and its effort to build strategic partners from national, regional, and international circles to bring greater progress and benefit to society.  For further information, please contact:     ​Tan Lay Eng  Communications Manager  layeng.tan@actxa.com   +65 9877 0406  Hasyimah Begum AJ  Communications Executive  hasyimah.aj@actxa.com   +65 8780 3620   About Actxa   Headquartered in Singapore, Actxa Pte Ltd is a deep tech company founded in 2015 that leverages artificial intelligence to create next generation preventive healthcare solutions.   We create evidence-based, personalized health insights in the domains of physical activities, sleep quality, body composition, stress and recovery, heart health and blood glucose evaluation and monitoring. ​​  To improve population health, Actxa establishes worldwide partnerships and research collaborations to develop critical preventive health models to help people avert chronic diseases such as diabetes and hypertension.​​  ​Learn more about Actxa at www.actxa.com .

10 June 2024   – Actxa Pte Ltd (“Actxa”), a Singaporean AI-driven deep tech company, has entered a Memorandum of Understanding (“MOU”) with the Diabetes and Hypertension Clinic (“DHC”) in India, a diabetes evaluation and management centre. The MOU, signed on 6 June 2024, marks a strategic step for Actxa to further research on diabetes prevention with artificial intelligence (“AI”) in India.   Since 2017, Actxa has been collaborating with research and medical institutions in Singapore in the research and development of non-invasive technology for detecting blood glucose elevation and diabetic risk assessment. The company completed its first clinical trial in 2022 and published its first scientific paper in 2023.  Actxa’s BGEM is the world’s first non-invasive blood glucose monitoring solution powered by an AI-driven algorithm that enables wearables and hearables with Photoplethysmography (PPG) sensors to assess the risk of impaired glucose regulation.​   In India, an estimated 77 million people above the age of 18 suffer from T2DM, with nearly 25 million classified as prediabetic [1]. Individuals with diabetes are at a higher risk for serious health issues, including heart attack, stroke and kidney failure. Over time, T2DM can damage blood vessels in the heart, eyes, kidneys and nerves [2].   This MOU seeks to broaden the study of non-invasive blood glucose monitoring using artificial intelligence in the Indian population. If successful, the non-invasive solution will be an affordable and user-friendly approach to promoting regular monitoring of blood glucose elevation and diabetic risk in India. Marcus Soo , Chief Executive Officer of Actxa , said, “We are happy to work with like-minded professionals like Dr. Abhinav Gupta of DHC. This collaboration showcases commitment from both Actxa and DHC, and our dedication to improving the lives of individuals affected by diabetes through innovation and excellence using advanced science and AI technology. Together with DHC, we aim to empower individuals in India with valuable insights into their diabetic health.”   Dr. Abhinav Gupta, MBBS, MD, FRCP, Professor of Medicine at ASCOMS,  shared, “Our collaboration with Actxa represents a pivotal milestone in our journey in advancing diabetes prevention and care.  Through research on AI-based algorithms for detecting hyperglycemia in diabetes patients, we are poised to make significant strides in early detection and treatment. This partnership underscores our dedication to harnessing cutting-edge technology for better health outcomes, aligning with the innovative BGEM technology.”   This collaboration between Actxa and DHC paves the way for groundbreaking advancements in diabetes prevention and care, contributing to a healthier future for individuals in Singapore, India and worldwide.    References: 1. World Health Organization, Diabetes in India: https://www.who.int/india/health-topics/mobile-technology-for-preventing-ncds 2. World Health Organization, Diabetes: https://www.who.int/news-room/fact-sheets/detail/diabetes     For further information, please contact: ​Tan Lay Eng Communications Manager layeng.tan@actxa.com +65 9877 0406 Hasyimah Begum AJ Communications Executive hasyimah.aj@actxa.com +65 8780 3620    About Actxa Headquartered in Singapore, Actxa Pte Ltd is a deep tech company founded in 2015 that leverages artificial intelligence to create next generation preventive healthcare solutions. ​ We create evidence-based, personalised health insights in the domains of physical activities, sleep quality, body composition, stress and recovery, heart health and blood glucose evaluation and monitoring. ​​ To improve population health, Actxa establishes worldwide partnerships and research collaborations to develop critical preventive health models to help people avert chronic diseases such as diabetes and hypertension.​​   ​Learn more about Actxa at www.actxa.com .   About Diabetes and Hypertension Clinic   Diabetes and Hypertension Clinic is a daycare setting run by Dr. Abhinav Gupta, who is a pioneer in the management of Diabetes and Hypertension. He has more than 15 years of experience in DHC, which is located in Channi Himmat Jammu, J&K, India.   Dr. Gupta has been awarded a fellowship of the Royal College of Physicians of London, Edinburgh and Glasgow.

Singapore, 17 July 2023 – Actxa, a homegrown AI-driven deep tech company, has launched the latest addition to its health and fitness monitoring product line, the Spark+ Series 2 ("Spark+ S2"), an activity tracker designed for all-round health and fitness monitoring. In comparison to Spark+ - its predecessor, the Spark+ S2 is enhanced with new and improved features such as SleepTrack™ , an advanced sleep tracking technology, All-Day Heart Rate (HR) and Heart Rate Variability (HRV) Monitoring , Outdoor Workouts with Real-Time Maps and VO2 Max. These extensive features are designed to help individuals better monitor and gain insights into their health and fitness. The Spark+ Series 2 is engineered to empower individuals in their journey towards better health and fitness. Whether you are an athlete, someone motivated to lose weight or aiming to lead a healthier lifestyle – using activity trackers has been associated with increased physical activity and improved health outcomes, including weight loss and cardiovascular health¹. SleepTrack™ Actxa's SleepTrack™ technology goes beyond basic sleep tracking by analysing various metrics to provide comprehensive insights into an individual’s sleep quality. Due to the importance of sleep in physical and mental well-being, significant attention has been focused on poor sleep patterns and insomnia among the public². The Spark+ S2 helps track sleep quality and generates detailed sleep reports for each sleep cycle, along with a sleep score that enables users to track sleep quality progress over time to ensure quality rest. All-Day Heart Rate (HR) and Heart Rate Variability (HRV) Monitoring The all-day heart rate (HR) and heart rate variability (HRV) monitoring provides valuable insights into how users' hearts respond to different activities and events. Whether awake, asleep, or engaged in workouts, the Spark+ S2 helps users understand their heart's performance and adapt accordingly. Outdoor Workouts with Real-Time Maps During outdoor workouts, the activity tracker also provides a real-time display of the workout route through users' phones’ GPS feature, enabling them to monitor the distance covered and track their progress with comprehensive performance reports. VO2 Max Actxa's advanced VO2 Max algorithm measures an individual’s fitness level and fitness age through a brisk walk or run. When users track their VO2 Max over time, they can monitor the effectiveness of their exercise routines and make informed decisions to optimise their fitness goals. With these enhanced and existing features, the Spark+ S2 provides users with valuable insights and data to optimise their well-being via the Actxa App, which conveniently generates reports of workout statistics, heart rate zones and heart rate performance during workouts. With the sleek, slim and fashionable Spark+ S2 activity tracker, harness your health and fitness potential and track your progress holistically. Take this opportunity to invest in your future by preventing or delaying chronic disease onset. Spark+ S2 is now available on Actxa's Lazada platform ( https://tinyurl.com/3ayrr9b7 ) for SGD$70. The Actxa app can be downloaded on the Google Play Store and Apple Store. Bulk purchases of 5, 10, or 20 trackers are also available via Lazada. For a higher quantity, contact Actxa's sales team at sales@actxa.com . Find out more about Actxa Spark+ Series 2 at https://www.actxa.com/spark-plus-series-2. References: Do Fitness Apps Really Help You Achieve a Healthier Lifestyle? ( https://healthyin.sg/fitness-apps-healthier-lifestyle/ ) Sleep quality of Singapore residents: findings from the 2016 Singapore mental health study ( https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8861160/#:~:text=Poor%20sleep%20has%20been%20linked,%5D%2C%20%5B11%5D%5D .) Download our Annex and Fact Sheet For further information, please contact: ​Tan Lay Eng Communications Manager layeng.tan@actxa.com +65 9877 0406 Hasyimah Begum AJ Communications Executive hasyimah.aj@actxa.com +65 8780 3620  About Actxa Headquartered in Singapore, Actxa Pte Ltd is a deep tech company founded in 2015 that leverages artificial intelligence to create next generation preventive healthcare solutions. ​ We create evidence-based, personalised health insights in the domains of physical activities, sleep quality, body composition, stress and recovery, heart health and blood glucose evaluation and monitoring. ​​ To improve population health, Actxa establishes worldwide partnerships and research collaborations to develop critical preventive health models to help people avert chronic diseases such as diabetes and hypertension.​​ ​Learn more about Actxa at www.actxa.com .

Singapore, 10 April 2023 – Actxa, Singapore's deep tech company leveraging artificial intelligence to create preventive healthcare solutions, has launched the Sense 2 Smart Scale ("Sense 2"), a professional grade segmental body composition analyser. Building on the success of its first-generation Sense smart scale, Sense 2 is introduced with enhanced accuracy and more customised insights to provide segmental composition analysis reports to help individuals improve their health and fitness. From 2019 to 2020, 20.7% of Singaporeans were in the high-risk Body Mass Index category for the Asian population and about one in 10 Singaporeans (10.5%) aged 18 to 74 years old were obese ¹ as compared to 8.6% in 2017 ² . Segmental analysis has been proven to be a valuable tool in monitoring disease progression and nutritional status in individuals with chronic injury or disease ³ . Beyond assessing up to 11 essential body measurements, Sense 2 provides users with holistic body composition analysis reports with more than 20 body composition indicators, including weight, body fat percentage, visceral fat level, muscle mass percentage, bone mass and total body water. It also trends up to the last ten measurements, allowing users to monitor and track their weight, muscle mass and percentage body fat (PBF) changes. Whether you are looking to lose weight for better health, attain fitness goals, sustain your current form, or get an insight into your body, Sense 2 is your perfect choice with its clear and comprehensive view of positive or negative lifestyle information. You can see which body composition relates to your fitness and health progress – the body fat mass or a muscle build-up, and then restructure your lifestyle habits to achieve your desired goals. Designed to cater to all ages and lifestyles, Sense 2 can support multiple users, allowing families to achieve their health goals together. The smart scale is especially useful for families with a history of diabetes, cardiovascular disease and obesity, as family members can keep close tabs on their weight and body composition in maintaining a healthy lifestyle. For users enrolled in Journey with Wellness, a corporate wellness programme curated by Actxa Wellness, a subsidiary of Actxa, Actxa Sense 2 Smart Scale is explicitly designed to support you in this wellness journey. Paired seamlessly with the Actxa mobile app via Bluetooth, the Sense 2 automatically syncs all measurements to the app, allowing users to monitor and track their progress easily through the body analysis report. In just one step, you can make more informed decisions to achieve your health and fitness goals faster and more efficiently. Most importantly, health consciousness and being proactive about health are critical to preventing or delaying chronic disease onset. The accurate readings of the analysis report are obtained through dual-frequency Bioelectrical Impedance Analysis (BIA) technology to provide a more precise body composition analysis than other scales using a single frequency. The technology is painless and safe, with a low-level electrical current sent through your body to analyse your body composition. Sense 2 also uses eight tactile electrodes to distinguish and measure a user's body in five segments (arms, trunk and legs) to deliver a more in-depth analysis report. Marcus Soo, Actxa's Chief Executive Officer, said, "Preventive health is a cornerstone in ensuring a healthier and better quality of life. It is also an important shift in Singapore's healthcare ecosystem. To support the nation's Healthier SG vision of promoting preventive care, we developed the Sense 2 as an affordable, easy-to-use and dependable healthy lifestyle companion to help everyone from all walks of life to monitor and better understand their bodies." Sense 2 is now available on Actxa's Lazada platform ( https://tinyurl.com/Sense-2 ) for SGD$150. The Actxa app can be downloaded on the Google Play Store and Apple Store. Find out more about Actxa Sense 2 at https://www.actxa.com/sense-2-smart-scale . References National Population Health Survey 2019/20 ( https://www.moh.gov.sg/resources-statistics/reports/national-survey-2019-20 ) Obesity in Singapore: It's Not a Small World ( https://www.healthhub.sg/live-healthy/764/its-not-a-small-world-after-all ) Comparison of segmental body composition estimated by bioelectrical impedance analysis and dual-energy X-ray absorptiometry ( https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6220710/ ) Download our Annex and Fact Sheet For further information, please contact Tan Lay Eng Communications Manager layeng.tan@actxa.com +65 9877 0406 Hasyimah Begum AJ Communications Executive hasyimah.aj@actxa.com +65 8780 3620 About Actxa Headquartered in Singapore, Actxa Pte Ltd is a deep tech company founded in 2015 that leverages artificial intelligence to create next generation preventive healthcare solutions. ​ We create evidence-based, personalised health insights in the domains of physical activities, sleep quality, body composition, stress and recovery, heart health and blood glucose evaluation and monitoring. ​​ To improve population health, Actxa establishes worldwide partnerships and research collaborations to develop critical preventive health models to help people avert chronic diseases such as diabetes and hypertension.​​ ​Learn more about Actxa at www.actxa.com .

For immediate release Singapore, 27 September 2021 – Actxa and KK Women’s and Children’s Hospital (KKH) are carrying out a clinical study to validate a non-invasive blood glucose predictive model on wearable devices with photoplethysmography (PPG) sensors developed by Actxa. The roles of wrist-worn and in-ear wearables with PPG sensors are constantly evolving. From being a lifestyle device that monitors sports and activities, to a device that monitors a person’s lifestyle well-being and health, foraying into preventive healthcare, particularly for the prevention of chronic diseases. Diabetes has been one of the “silent” chronic diseases, and research has shown that diabetic patients have a two to three-fold higher risk of developing cardiovascular disease. In Singapore and globally, diabetes and cardiovascular diseases are serious health concerns resulting in poor quality of life. Leveraging on its expertise and knowledge of wrist-worn and in-ear wearables, Actxa has developed a predictive model based on Artificial Intelligence and Machine Learning (AIML) for PPG sensors to monitor blood glucose level non-invasively. The collaboration with KKH will enable Actxa to externally validate the predictive model developed against an independent population, further improving the model’s diagnostic ability. Joel Chin, CEO of Actxa , said, “We are excited about this collaboration as the predictive model will be able to facilitate early detection and intervention of diabetes that will make a significant positive impact in the preventive health arena. It will also provide valuable insights into wearables’ potential in providing continuous and accurate real-time data that can aid patients, whose blood sugar is in the diabetes and pre-diabetes range, to self-manage their disease better and earlier.” Associate Professor Ang Seng Bin, Head and Senior Consultant, Family Medicine Service, KKH , who is also the principal investigator of this research at KKH, said, “As Singapore’s largest academic medical centre specialising in women’s and children’s health, KKH is committed to improving patient health outcomes. Through this new collaboration, we hope that we can harness the power of technology to make a difference in patients’ lives, especially those with diabetes.” This clinical study will be carried out jointly by the following Principal Investigators – Associate Professor Ang Seng Bin (KKH), Emeritus Professor Satvinder Singh Dhaliwal (Actxa) and Mr Shi Bohan (Actxa). Results and findings from this clinical study are to be published in the second half of 2022 in peer-reviewed scientific journals. Actxa will carry out more clinical trials in the near future to provide further clinical evidence for new products. About Actxa Headquartered in Singapore, Actxa Pte.Ltd (“Actxa”) was founded in 2015 with the mission to have deep empathy and harness the power of science and data to empower people to lead healthier lives. At Actxa, we inspire individuals from all walks of life to make proactive moves to live better and healthier. Leveraging data analytics, artificial intelligence, and machine learning, we create evidence-based, personalised health insights in the domains of physical activities, sleep quality, body composition, stress and recovery, heart health and non-invasive blood glucose monitoring. With the help of these insights, Actxa develops applications such as Healthy Living Score (HLS), Actxa Wellness Programme (AWP) and products to empower individuals to manage and improve their own health. To improve population health, Actxa establishes worldwide partnerships and research collaborations to develop critical preventive health models to help people avert chronic diseases such as diabetes and hypertension. Good health and happiness go hand-in-hand. Actxa is committed to taking the lead to create Better Moves, Better Lives to better ourselves, the people around us and our community. For further information, please contact: Tan Lay Eng Corporate Communications Manager layeng.tan@actxa.com +65 98770406

(Media source: MediaCorp 8world) Actxa　健康分析 Actxa迎来专业级别的智能体重秤和身体成分分析仪“Sense 2 Smart Scale”。这个新品的研发乃基于其第一代的成功，“Sense 2”的出现，则具有更高的准确性和更多的定制化，可提供分段成分分析报告，帮助个人改善健康状况。 此新品采用了八个触觉电极和双频生物电阻抗分析 (BIA) 技术，可评估多达11项的基本身体测量值，为用户提供包含 20 多项身体成分指标的整体分析报告。 它还会显示最近十次的测量值趋势，让用户能够监控及跟踪自己的体重、肌肉质量和体脂百分比 (PBF) 的变化。 “Sense 2”可支持多个用户的使用，让一家人一起实现健康目标。售价$150。 哪里买 ： https://tinyurl.com/yck6wfct

19 October 2023 – Actxa, a Singapore-based AI-driven deep tech company, and Umeox, a leader in wearables manufacturing and solutions, have entered a strategic collaboration to integrate Actxa’s cutting-edge non-invasive Blood Glucose Evaluation & Monitoring solution, BGEM , into Umeox’s upcoming product lineup, including health rings and smartwatches. BGEM by Actxa is the world's first non-invasive blood glucose monitoring solution that leverages the latest technological advancement in signal processing, wearable technologies, and artificial intelligence (“AI”) to assess the risk of impaired glucose regulation. The heart of BGEM lies in its ability to use inter-beat-interval data from a consumer-grade wearables photoplethysmography (“PPG”) sensor. Using its advanced AI model, BGEM computes the relevant digital biomarkers correlated with the symptoms of prediabetes or Type 2 diabetes mellitus (“T2DM”) that eventually predicts the risk of developing diabetes. A powerful health awareness tool, BGEM empowers individuals to monitor and assess their glucose dysregulation in a non-invasive, easy and frequent manner. With continuous monitoring and evaluation of diabetic risks, individuals can take proactive measures in making informed health decisions and positive lifestyle changes to reduce the risk of T2DM development. Marcus Soo, Chief Executive Officer of Actxa , said, “As a company with a vision to help people live healthier and longer with technology, we aspire to translate technological innovations into evident solutions that enhance lives. Collaborating with pioneering industry players like Umeox aligns with our vision. The fusion of their products with our BGEM solution holds the potential to empower more people to take proactive actions to prevent, delay the onset or even reverse the condition of diabetes. This strategic collaboration not only expedites the development, market accessibility and future commercialisation of BGEM but also tangibly contributes to building healthier individuals and communities. We look forward to a successful partnership with Umeox.” Jack Shao, Founder and Chief Executive Officer of Umeox , said, “Over the course of 17 years, we have remained dedicated to empowering people to live healthier. Our products have consistently demonstrated their ability to enhance people’s overall well-being. We believe our latest smart ring model, X ring, has immense potential to positively transform preventive healthcare and empower individuals to take control of their well-being through continuous, unobtrusive health monitoring. Working in tandem with Actxa to integrate BGEM into our upcoming product releases enables us to address evolving consumer needs effectively. This strategic collaboration reflects the shared commitment of both companies to unlock new opportunities in the global preventive health market, and we hope this strategic collaboration will be a great start for the two parties’ long-term partnership.” BGEM has won Actxa an award under the AI – Healthcare Technology category in the annual SBR Technology Excellence Awards 2022, hosted by Singapore Business Review. For further information, please contact: ​Tan Lay Eng Communications Manager layeng.tan@actxa.com +65 9877 0406 Hasyimah Begum AJ Communications Executive hasyimah.aj@actxa.com +65 8780 3620  About Actxa Headquartered in Singapore, Actxa Pte Ltd is a deep tech company founded in 2015 that leverages artificial intelligence to create next generation preventive healthcare solutions. ​ We create evidence-based, personalised health insights in the domains of physical activities, sleep quality, body composition, stress and recovery, heart health and blood glucose evaluation and monitoring. ​​ To improve population health, Actxa establishes worldwide partnerships and research collaborations to develop critical preventive health models to help people avert chronic diseases such as diabetes and hypertension.​​ ​Learn more about Actxa at www.actxa.com . About Umeox Umeox is a high-tech and innovative enterprise of software, hardware, service integrated Solution. It develops and produces intelligent terminals which are based on IoT and AI technology, as well as providing operators and vendors around the world with one-stop solution services, including hardware manufacturing, software development, location management, AI interaction, health care, and intelligent data management cloud platform. Based on strong R&D ability and professional service, Umeox always adheres to high-quality strategy, keeps up with hot market demand and trend, constantly explores cutting-edge technology of scientific and technological innovation, closely combines humanistic care, and continuously provides customers with high-quality and cost-effective customised products and full turnkey solutions. ​Learn more about Umeox at www.umeox.com .

4 April 2024   – Actxa Pte Ltd (“Actxa”), an AI-driven deep tech company headquartered in Singapore, has signed a Memorandum of Agreement (“MOU”) with Instytut Medycyny Innowacyjnej sp.z o.o. (“IMI”), a research and medical technologies institute based in Poland on 7 March 2024. This MOU marks the beginning of a strategic partnership for collaboration and market distribution of Actxa’s BGEM, a non-invasive Blood Glucose Evaluation and Monitoring Technology  and other Actxa technologies in Poland. At the heart of this partnership is Actxa’s groundbreaking BGEM technology - the world's first non-invasive blood glucose monitoring technology. Harnessing the power of artificial intelligence ("AI"), wearable technologies and signal processing, BGEM tracks and identifies the risk of impaired glucose regulation.     By analysing inter-beat-interval data from consumer-grade wearables equipped with photoplethysmography ("PPG") sensors, BGEM calculates the digital biomarkers associated with prediabetes or Type 2 diabetes mellitus ("T2DM") symptoms, empowering users to monitor, track, and identify fluctuations in their blood glucose levels. This proactive approach allows users to implement timely lifestyle adjustments, effectively mitigating the risk or delaying the onset of diabetes.    Under this partnership, IMI will be an authorised licensee with the rights to use BGEM and incorporate the technology in its brand of wearable products for distribution in Poland. Additionally, IMI will play a pivotal role in facilitating the exploration of opportunities within countries, governments and industries to sell and market wearables with BGEM and other Actxa technologies.   Marcus Soo, Chief Executive Officer of Actxa , said, “Our collaboration with IMI signifies an important milestone in our journey toward global expansion. This collaboration is a testament to our commitment to innovation and excellence in the tech industry. Together with IMI, we embark on a transformative endeavour, combining our strengths to propel our business to new heights internationally.   This alliance not only strengthens our position in the global market but also allows our technologies, such as BGEM, to benefit a broader community. As we join forces with IMI, we are poised for unparalleled growth, setting the stage for a future defined by international success and groundbreaking achievements.”    Founder of IMI, Professor Mieczysław Pasowicz  shared, “At IMI, we are driven by a shared vision for a future where healthcare is transformed through innovation. Our collaboration with Actxa speaks to our unwavering dedication as we bring their groundbreaking technologies to Poland. Our strategic partnership aims to revolutionise healthcare, fostering a future where cutting-edge solutions positively impact lives. This partnership represents a significant stride towards a healthier and more technologically advanced world.” This alliance between Actxa and IMI sets the stage for Actxa’s innovative technologies to expand globally. As both companies continue to leverage their strengths and expertise, they are poised to drive positive change and contribute to the advancement of a healthier world.  For further information, please contact: ​Tan Lay Eng Communications Manager layeng.tan@actxa.com +65 9877 0406 Hasyimah Begum AJ Communications Executive hasyimah.aj@actxa.com +65 8780 3620  About Actxa Headquartered in Singapore, Actxa Pte Ltd is a deep tech company founded in 2015 that leverages artificial intelligence to create next generation preventive healthcare solutions. ​ We create evidence-based, personalised health insights in the domains of physical activities, sleep quality, body composition, stress and recovery, heart health and blood glucose evaluation and monitoring. ​​ To improve population health, Actxa establishes worldwide partnerships and research collaborations to develop critical preventive health models to help people avert chronic diseases such as diabetes and hypertension.​​ ​Learn more about Actxa at www.actxa.com . About Instytut Medycyny Innowacyjnej sp.z o.o   For nearly 30 years Prof. Mieczysław Pasowicz has been creating and implementing initiatives related to the adaptation of hospitals to European Union standards through the creation and implementation of innovative investment projects. He specializes in investment and hospital development, healthcare management and training and digital transformation. It promotes the development of personalized medicine, coordinated healthcare and digital medicine. This is possible thanks to the involvement in modern technologies, advanced treatment methods and continuous training of medical personnel. Prof. Mieczysław Pasowicz is the founder and president/CEO of the Institute.  The Institute of Innovative Medicine is a spin-off company established to commercialize research and implement new medical technologies. The company is the initiator of the creation of the BioMedTech Technology Park, the aim of which is to transfer technology from Asia to Europe and is currently looking for Partners and Investors interested in co-creating the Longevity Technology Park using the latest developments in medical robotics,  biotechnology, IT, artificial intelligence and other medical technologies. It already has a modern facility with an area of 18 thousand m2 and an investment area for the creation of the Park ( www.medtechpoland.eu ).   Leading programs promoting organizational, product and technological innovations, the Institute of Innovative Medicine together with its partners achieves better results and market position in many areas. The Institute provides consulting and training services, provides specialized IT systems and medical equipment and offers management of healthcare facilities. It has several medical teams and cooperates with more than 100 specialists both at home and abroad. The Institute and BioMedTech Park will support young companies, innovative products and proven technologies, introducing them to domestic and international markets on behalf of customers and through sales programs.  Prof. Dr hab. med. Mieczysław Pasowicz is a long-time director of the John Paul II Hospital in Krakow and vice-president of the European Association of Hospital Managers (EAHM). He is the founder and also serves as the president of the Polish Association of Hospital Directors. Prof. Pasowicz is a long-term academic lecturer with significant medical, scientific and organizational achievements.